Revolutionizing Healthcare
Artificial Blood Institute in Boston
Welcome to the Artificial Blood Institute
The Artificial Blood Institute has for its goal; the creation of a safe and effective artificial blood composition for transfusion into humans that is low in cost to produce and stable over extended periods of time. The Institute has developed a concept for the creation for such an artificial blood product and has recently filed several patent applications in the United States for this composition. The Institute intends to file additional patent applications worldwide as the concept is further developed. The Institute is publicly disclosing its artificial blood concept on this website and is seeking those involved in research, especially those involved in research on artificial blood and/or iron complexes of amino acids. to cooperate with the Institute in bringing such an artificial blood composition to commercialization. As an incentive to those involved in such research, if an individual or organization can demonstrate that it has such a commercially acceptable composition based upon the Institute’s concepts, the Institute will grant a world-wide license pursuant to the Institute’s patent holding to said individual or organization to make, use, sell and sublicense the artificial blood product for a license fee of 2.5% of net sales and 2.5% of royalty income, if any.
Working to End Blood Shortages
Circumstances such as accidents, surgery, traumatic hemorrhagic shock, and other casualties cause major blood loss. Allogenic blood transfusion can be resuscitative for such conditions; however, it has numerous ambivalent effects, including supply shortage, needs for more time, cost for blood grouping, the possibility of spreading an infection, and short shelf-life. Hypoxia or ischemia causes heart failure, neurological problems, and organ damage in many patients. To address this emergent medical need for resuscitation and to treat hypoxic conditions as well as to enhance oxygen transportation, researchers aspire to achieve a robust technology with an object of developing safe and feasible blood substitutes, or artificial blood, for effective oxygen transport.
Unraveling the Potential of Artificial Blood
Though efforts to develop an artificial blood based upon hemoglobin are in clinical trials, the required hemoglobin needed for the formulation of an artificial blood product relies upon using either native or recombinant human hemoglobin, modified forms of human hemoglobin or modified forms of hemoglobin from other species. Unmodified hemoglobin can be used as an oxygen therapeutic; however, it can bind NOx and causes severe vasoconstriction and hypertension. As a consequence of its molecular weight, hemoglobin can cause significant toxicities, especially to the kidney where it clogs the glomerular apparatus. As a consequence, the majority of tested hemoglobin in humans is modified to prolong their half-life and reduce their toxicity. Consequently, hemoglobin as an artificial blood is costly and difficult to acquire and store.
The Institute's Goal
The Artificial Blood Institute is not seeking monetary benefit from the development of the artificial blood composition derived from its concept.. Instead, it is offering any interested party the opportunity to participate in the development of such a product. Income generated by the Institute derived from its patent estate or other source of income will be used by the Institute to provide grants to those engaged in meaningful artificial blood research as determined by the Institute. Any interested party should feel free to contact the Institute using the contact information provided in this website.
Stay Informed and Inspired
The Artificial Blood Institute strives to keep you informed and engaged with groundbreaking articles. Visitors to this website are invited to submit their comments and any articles of interest. Check our website for updates as we delve into the fascinating world of artificial blood research. From breakthrough discoveries to innovative technologies, we'll deliver the latest updates submitted to us to your screen. Join us on this cutting-edge journey as we explore the endless possibilities of artificial blood. Get ready to be inspired, educated, and amazed.
Conclusion
The Andre Danesh Artificial Blood Institute is not seeking monetary benefit from the development of the artificial blood composition discussed above. Instead, it is offering any interested party the opportunity to participate in the development of such a product. Income generated by the Institute derived from its patent estate or other source of income will be used by the Institute to provide grants to those engaged in meaningful artificial blood research as determined by the Institute. Any interested party should feel free to contact the Institute using the contact information provided in this website.
Get in Touch with us Today
We'd love to hear from you. Fill out the form below, and we'll be in touch as soon as possible.
Contact Us
Frequently Asked Questions
Have a question? We're here to help.
Artificial Blood Institute
The information provided by the Andre Danesh Artificial Blood Institute. and any and all individuals associated with the Institute or operating on its behalf, is for general informational purposes. All information on this site is provided in good faith, however no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, availability or completeness of any information provided on this site. UNDER NO CIRCUMSTANCES SHALL THE INSTITUTE HAVE ANY LIABILITY TO ANY USER OF THIS SITE FOR ANY LOSS OR DAMAGE OF ANY KIND INCURRED AS A RESULT OF THE USE OF THIS SITE OR RELIANCE ON ANY INFORMATION PROVIDED ON THIS SITE. USE OF THIS SITE AND RELIANCE ON ANY INFORMATION ON THIS SITE IS SOLELY AT YOUR OWN RISK.
Copyright 2024 The Andre Danesh Artificial Blood Institute, LLC